MA39722A - Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 - Google Patents
Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11Info
- Publication number
- MA39722A MA39722A MA039722A MA39722A MA39722A MA 39722 A MA39722 A MA 39722A MA 039722 A MA039722 A MA 039722A MA 39722 A MA39722 A MA 39722A MA 39722 A MA39722 A MA 39722A
- Authority
- MA
- Morocco
- Prior art keywords
- gdf11
- activin
- anemia
- inhibition
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969073P | 2014-03-21 | 2014-03-21 | |
| US201462021923P | 2014-07-08 | 2014-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39722A true MA39722A (fr) | 2021-06-02 |
Family
ID=54145413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA039722A MA39722A (fr) | 2014-03-21 | 2015-03-20 | Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160046690A1 (fr) |
| EP (1) | EP3119418B1 (fr) |
| JP (2) | JP2017509647A (fr) |
| KR (2) | KR102520970B1 (fr) |
| CN (1) | CN106659769A (fr) |
| AU (3) | AU2015231022B2 (fr) |
| CA (1) | CA2942954A1 (fr) |
| MA (1) | MA39722A (fr) |
| WO (1) | WO2015143403A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| RU2018145985A (ru) | 2012-11-02 | 2019-02-18 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| EP3212213B1 (fr) | 2014-10-30 | 2021-04-28 | Acceleron Pharma Inc. | Méthodes et compositions utilisant des polypeptides gdf15 pour augmenter le nombre de globules rouges sanguins |
| DK3227675T3 (da) | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| DK3286206T3 (da) | 2015-04-22 | 2021-05-03 | Biogen Ma Inc | Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme |
| EP3370754A4 (fr) | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | Méthodes pour augmenter les taux d'érythrocytes et traiter l'érythropoïèse inefficace |
| CA3005975A1 (fr) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methode de traitement de troubles oculaires |
| EA201990226A1 (ru) | 2016-07-27 | 2019-08-30 | Акселерон Фарма Инк. | Способы и композиции для лечения миелофиброза |
| CN109996817A (zh) * | 2016-09-15 | 2019-07-09 | 艾科赛扬制药股份有限公司 | 扭转原肠胚形成多肽及其用途 |
| JP7280182B2 (ja) | 2016-10-05 | 2023-05-23 | アクセルロン ファーマ インコーポレイテッド | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| WO2018089715A1 (fr) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Variants de type iia du récepteur de l'activine et leurs méthodes d'utilisation |
| SMT202400437T1 (it) | 2017-06-14 | 2024-11-15 | Celgene Corp | Metodi per trattare mielofibrosi associata a neoplasia mieloproliferativa e anemia |
| CN107828719B (zh) * | 2017-09-14 | 2020-05-19 | 暨南大学 | Gdf11在脂肪间充质干细胞成骨分化中的应用 |
| KR20250059538A (ko) | 2017-11-09 | 2025-05-02 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| JP7510875B2 (ja) | 2018-01-12 | 2024-07-04 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物 |
| EP3788065B1 (fr) * | 2018-04-30 | 2025-08-27 | The Children's Hospital Of Philadelphia | Atténuation d'anémies par combinaison d'agents |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CN115279392A (zh) * | 2020-01-20 | 2022-11-01 | 鲁达库尔公司 | 治疗trpv1活性介导疾病的药物组合物 |
| KR20230004515A (ko) | 2020-03-20 | 2023-01-06 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법 |
| EP4121088A4 (fr) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Procédés d'utilisation de variants de récepteur de l'activine de type iib |
| WO2023212296A1 (fr) * | 2022-04-29 | 2023-11-02 | University Of Massachusetts | Agents de modulation d'arn sélectifs |
| WO2025040002A1 (fr) * | 2023-08-21 | 2025-02-27 | 苏州炫景生物科技有限公司 | Oligonucléotide double brin ciblant un gène inhbe, conjugué, composition et utilisation associée |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0610248A2 (pt) * | 2005-04-25 | 2010-06-08 | Pfizer | anticorpos contra miostatina, composição farmacêutica compreendendo os mesmos, linhas celulares que os produzem , moléculas de ácido nucleico codificantes dos mesmos bem como seus usos |
| US8128933B2 (en) * | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| CN104524548A (zh) * | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| LT3750552T (lt) * | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| MX385318B (es) * | 2009-06-08 | 2025-03-18 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| CA2770822C (fr) * | 2009-08-13 | 2020-03-24 | Acceleron Pharma Inc. | Utilisation combinee de pieges gdf et d'activateurs du recepteur de l'erythropoietine pour augmenter les taux de globules rouges |
| WO2012027065A2 (fr) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Polythérapie pour traiter des maladies |
| EP3520805B1 (fr) * | 2011-10-17 | 2021-03-10 | Acceleron Pharma Inc. | Procédés et compositions pour traiter de la myélofibrose |
| WO2013164444A1 (fr) * | 2012-05-03 | 2013-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédé et composition pharmaceutique destinés à être utilisés dans le traitement et le diagnostic de l'anémie inflammatoire |
| JP6401172B2 (ja) * | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
-
2015
- 2015-03-20 KR KR1020227044659A patent/KR102520970B1/ko active Active
- 2015-03-20 MA MA039722A patent/MA39722A/fr unknown
- 2015-03-20 AU AU2015231022A patent/AU2015231022B2/en not_active Ceased
- 2015-03-20 EP EP15765863.4A patent/EP3119418B1/fr active Active
- 2015-03-20 KR KR1020167029253A patent/KR20160127148A/ko not_active Ceased
- 2015-03-20 JP JP2016557982A patent/JP2017509647A/ja not_active Withdrawn
- 2015-03-20 CA CA2942954A patent/CA2942954A1/fr active Pending
- 2015-03-20 CN CN201580024704.5A patent/CN106659769A/zh active Pending
- 2015-03-20 WO PCT/US2015/021880 patent/WO2015143403A1/fr not_active Ceased
- 2015-03-20 US US14/664,651 patent/US20160046690A1/en not_active Abandoned
-
2020
- 2020-04-24 JP JP2020077142A patent/JP7154250B2/ja active Active
- 2020-07-02 US US16/919,377 patent/US20210155672A1/en not_active Abandoned
-
2021
- 2021-01-19 AU AU2021200301A patent/AU2021200301A1/en not_active Abandoned
-
2023
- 2023-08-23 AU AU2023219885A patent/AU2023219885A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015231022B2 (en) | 2021-02-04 |
| US20210155672A1 (en) | 2021-05-27 |
| KR20160127148A (ko) | 2016-11-02 |
| JP2017509647A (ja) | 2017-04-06 |
| JP7154250B2 (ja) | 2022-10-17 |
| EP3119418A4 (fr) | 2018-01-03 |
| JP2020111621A (ja) | 2020-07-27 |
| KR20230004942A (ko) | 2023-01-06 |
| CA2942954A1 (fr) | 2015-09-24 |
| KR102520970B1 (ko) | 2023-04-12 |
| CN106659769A (zh) | 2017-05-10 |
| EP3119418A1 (fr) | 2017-01-25 |
| AU2021200301A1 (en) | 2021-03-18 |
| AU2015231022A1 (en) | 2016-09-29 |
| AU2023219885A1 (en) | 2023-09-14 |
| EP3119418B1 (fr) | 2022-02-23 |
| WO2015143403A1 (fr) | 2015-09-24 |
| US20160046690A1 (en) | 2016-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39722A (fr) | Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 | |
| EP3374502A4 (fr) | Procédés pour le traitement de dystrophies cornéennes | |
| EP3302379A4 (fr) | Compositions et méthodes pour le traitement du ptérygion | |
| EP3347469A4 (fr) | Méthodes et compositions pour le traitement du glaucome | |
| EP3368559A4 (fr) | Compositions et méthodes pour le du traitement du cancer | |
| EP3233878A4 (fr) | Phosphoramidates pour le traitement du virus de l'hépatite b | |
| EP3390642A4 (fr) | Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13 | |
| EP3380200A4 (fr) | Compositions pour le traitement des cheveux | |
| EP3377516A4 (fr) | Procédés et compositions pour le traitement du cancer | |
| EP3341391A4 (fr) | Compositions et procédés pour le traitement de la douleur | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| EP3503890A4 (fr) | Utilisation de la pridopidine pour le traitement des dystonies | |
| EP3380063A4 (fr) | Compositions pour le traitement des cheveux | |
| EP3334432A4 (fr) | Cerdulatinib pour le traitement du myélome | |
| EP3347025A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| EP3429609A4 (fr) | Compositions et procédés pour le traitement de déficits en collagène de type vii | |
| EP3353204A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| MA43230A (fr) | Méthodes et compositions pour le traitement d'une épidermolyse bulleuse | |
| EP3386967A4 (fr) | Combinaisons pour le traitement de calculs rénaux | |
| EP3522865A4 (fr) | Méthodes et compositions pour le traitement de vergetures | |
| EP3386593A4 (fr) | Composition immunomodulatrice pour le traitement | |
| MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple | |
| EP3329929A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement de la sécheresse oculaire | |
| EP3331545A4 (fr) | Agents spécifiques du domaine extracellulaire de l'hémicanal pour traitement de la septicémie | |
| EP3373922A4 (fr) | Compositions et méthodes pour le traitement de l'homocystinurie |